The Technical Analyst
Citius Pharmaceuticals [CTXR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Citius Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-6.62% $0.717
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 113.99 mill |
| EPS: | -0.260 |
| P/E: | -2.76 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 159.10 mill |
| Avg Daily Volume: | 0.841 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.76 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.47x |
| Company: PE -2.76 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.172 (-76.02%) $-0.545 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.647 - 0.787 ( +/- 9.77%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-03 | Mazur Leonard L | Buy | 1 165 048 | Warrant to Purchase Common Stock |
| 2024-04-03 | Mazur Leonard L | Sell | 1 165 048 | Warrant to Purchase Common Stock |
| 2024-04-03 | Holubiak Myron Z | Buy | 129 450 | Warrant to Purchase Common Stock |
| 2024-04-03 | Holubiak Myron Z | Sell | 129 450 | Warrant to Purchase Common Stock |
| 2024-03-14 | Smith Robert Joseph | Buy | 75 000 | Stock Option (Right to Purchase Common Stock) |
| INSIDER POWER |
|---|
| 43.41 |
| Last 96 transactions |
| Buy: 27 334 255 | Sell: 1 367 765 |
Forecast:
16:00 - $0.719
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.719
Forecast 2: 16:00 - $0.719
Forecast 3: 16:00 - $0.719
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.717 (-6.62% ) |
| Volume | 0.877 mill |
| Avg. Vol. | 0.841 mill |
| % of Avg. Vol | 104.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CTXR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CTXR
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-04-11 08:30:00 - Press Release
Citius Pharmaceuticals Announces Addition Of City Of Hope To Umn's Phase 1 Trial Of Lymphir In Combination With Car-t For The Treatment Of B-cell Lymphoma
National cancer institute (nci)-designated research and treatment center city of hope, in duarte, ca, to participate in the university of minnesota (umn) masonic cancer center's ongoing phase 1 trial to determine the maximum tolerated dose of lymphir plus car-t therapy cranford, n.j. , april 11, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the university of minnesota masonic cancer center intends to expand their ongoing investigator-initiated phase 1 trial of lymphir™ (denileukin diftitox) in combination with fda-approved car-t products for the treatment of b-cell lymphomas.
2024-04-04 08:30:00 - Press Release
Citius Pharmaceuticals To Present At The Ld Micro Invitational Xiv Investor Conference
Cranford, n.j. , april 4, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that chairman and ceo leonard mazur will present at the 14th annual ld micro invitational investor conference being held april 8-9, 2024, in new york city.
2024-03-18 08:30:00 - Press Release
Citius Pharmaceuticals Announces Fda Acceptance Of The Bla Resubmission Of Lymphir™ (denileukin Diftitox) For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-cell Lymphoma
Fda assigns prescription drug user fee act (pdufa) target action date of august 13, 2024 cranford, n.j., march 18, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the u.s. food and drug administration (fda) has accepted the resubmission of the company's biologics license application (bla) for lymphir™ (denileukin diftitox), an il-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous t-cell lymphoma (ctcl) after at least one prior systemic therapy.
2024-03-07 08:30:00 - Press Release
Citius Pharmaceuticals, Inc. Secures $2.4 Million Through New Jersey Economic Development Program
Net operating losses converted into non-dilutive capital cranford, n.j. , march 7, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the company has received $2.4 million in non-dilutive capital through new jersey's technology business tax certificate transfer program, more commonly known as the net operating loss (nol) program, funded through the new jersey economic development authority (njeda).
2024-02-26 07:30:00 - Press Release
Citius Pharmaceuticals Announces Filing Of Form S-3 Shelf Registration Statement To Replace Expiring Prior Shelf Registration
Cranford, n.j. , feb. 26, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the company filed a form s-3 shelf registration on february 23, 2024 with the securities and exchange commission to replace its currently effective shelf registration statement that expires in april 2024 pursuant to sec rules.
Latest News
2024-02-23 08:30:00 - PRNewsWire
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
CRANFORD, N.J. , Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences.
2023-09-18 16:30:00 - PRNewsWire
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, has rescheduled its participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for the late Howard Safir, a long-time member of the Citius Board.
2023-09-06 16:30:00 - PRNewsWire
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023.
2023-06-02 18:55:19 - Seeking Alpha
Citius Pharmaceuticals: Steer Clear From This One
The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2023 PDUFA; it has generated excitement among investors, although it is unlikely to generate alpha. Its second lead therapy is likely to disappoint.
2023-01-11 08:30:00 - PRNewsWire
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.
2022-12-28 10:51:29 - Zacks Investment Research
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-11-08 07:36:20 - Seeking Alpha
Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days
Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway far enough to reach commercialization of its major products, and are therefore a "must complete" by the company.
2022-09-08 16:30:00 - PRNewsWire
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
UPDATED: Chairman & CEO of Citius, Leonard Mazur, to present September 12, 2022 at 8:30am ET CRANFORD, N.J. , Sept. 8, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C.
2022-07-05 18:40:12 - Seeking Alpha
Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated.
2022-05-18 09:30:00 - PRNewsWire
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
CRANFORD, N.J. , May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C.